Circulation, Vol 73, 476-483, Copyright © 1986 by American Heart Association
P Charbonneau, A Syrota, C Crouzel, JM Valois, C Prenant and M Crouzel
The presence of specific benzodiazepine binding sites in the hearts of dogs
and human beings was demonstrated in vivo by a noninvasive method, positron
emission tomography (PET). An antagonist of the peripheral- type
benzodiazepine binding site, PK 11195, was labeled with carbon-11, a
short-lived positron emitter. When injected at high specific activity,
11C-PK 11195 was concentrated in the myocardium. As increasing amounts of
unlabeled PK 11195 were added to the radioactive ligand, the myocardial
ligand concentration was proportional to myocardial regional perfusion up
to quantities of 40 nmol/kg body weight. Above 40 nmol/kg the ligand
concentration reached a maximum value (6000 pmol/cm3), which could be
considered as the total number of binding sites per unit heart volume. The
specificity of 11C-PK 11195 binding to canine heart was demonstrated from a
study on the inhibition of binding for radioligand by an excess of several
agonists or antagonists of benzodiazepine receptor. The distribution and
specificity of 11C-PK 11195 was similar in dogs and in human beings. PET
thus opens the way to the investigation of the peripheral-type
benzodiazepine receptor in a clinical situation, since it has recently been
shown that this receptor could be coupled to the calcium channel in the
heart.
ARTICLES
Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1986 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |